Dayvigo Side Effects: Severity Distribution by Patient Phenotype

What Dayvigo is and why phenotype matters

Dayvigo (lemborexant) is approved by the FDA for adults with insomnia characterized by difficulties with sleep onset or sleep maintenance. Unlike benzodiazepines and Z-drugs, it does not broadly suppress the central nervous system. Instead, it selectively blocks orexin receptors, cutting off the brain's chemical "stay awake" signal. That targeted mechanism generally produces a more favorable side-effect profile than older sedative-hypnotics.

Yet "generally favorable" does not mean uniform. The severity and type of adverse events you experience depend heavily on your phenotype, a term that here covers your hormonal environment, age, liver metabolism, concurrent diagnoses, and the medications you already take. A 32-year-old woman with regular cycles and no comorbidities faces a different risk field than a 54-year-old in perimenopause taking an SSRI and a CYP3A4-inhibiting antifungal.

This article breaks down what the clinical trial data, FDA labeling, and post-market surveillance actually show about side-effect severity, and maps those findings onto the phenotypes most relevant to women at different life stages.

The SUNRISE trial data: what adverse events actually look like

The key evidence for lemborexant comes from the SUNRISE 1 and SUNRISE 2 trials, two phase 3 randomized controlled studies that enrolled adults with chronic insomnia disorder.

Somnolence: the dominant signal

SUNRISE 1 compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg over one month. Somnolence was the most frequently reported adverse event. In SUNRISE 1, somnolence occurred in 10% of patients on lemborexant 5 mg and 17% on lemborexant 10 mg, compared with 7% on zolpidem ER and 1% on placebo. Most episodes were mild to moderate in intensity and did not lead to discontinuation.

SUNRISE 2 extended follow-up to 12 months and confirmed that somnolence rates did not worsen over time. The rate stabilized rather than accumulated, which is a meaningful distinction from tolerance-forming agents where escalating doses drive worsening adverse events over time.

Headache and nasopharyngitis

Headache was the second most common adverse event across both trials, occurring in roughly 5-7% of participants at therapeutic doses. Nasopharyngitis appeared at similar rates. Both were predominantly mild and self-limited.

Next-day driving impairment

Next-day residual effects matter for women who drive, commute, or operate equipment early in the morning. A dedicated driving simulation study published in Sleep found that lemborexant 10 mg produced statistically significant impairment on a standardized driving test at 9 hours post-dose versus placebo. The 5 mg dose did not reach statistical significance at 9 hours. The FDA incorporated this finding into the prescribing information, recommending that patients not drive or operate heavy machinery the morning after taking 10 mg if they slept fewer than a full night.

Serious adverse events from the trials

Serious adverse events were infrequent in SUNRISE 1 and SUNRISE 2. Complex sleep behaviors, including sleep-walking and sleep-eating, were each reported in <1% of trial participants. The FDA prescribing label carries a boxed warning for complex sleep behaviors, noting that some have resulted in serious injury and death when patients engaged in activities such as driving while not fully awake.

Severity distribution by phenotype: a framework for real women

No published trial has formally stratified lemborexant adverse events by female phenotype. The following framework synthesizes FDA pharmacokinetic data, subgroup analyses from SUNRISE, and post-market FAERS reports to map severity probability onto clinically meaningful patient types. Where data are extrapolated rather than directly studied in women, that is stated explicitly.

Phenotype 1: Reproductive-age women (18-40), generally healthy

For women in their reproductive years with intact liver function, no significant comorbidities, and no interacting medications, lemborexant 5 mg sits in a low-severity adverse-event zone for most outcomes.

Somnolence is still the most likely effect. At 5 mg, most women describe it as "groggy on waking" rather than sedation that persists into midday. The SUNRISE data do not break out adverse-event rates by sex separately for this age group, so the overall trial rates (10% somnolence at 5 mg) serve as the best available estimate.

One consideration specific to reproductive-age women: lemborexant's effect on sleep architecture preserves REM sleep better than benzodiazepines, which is relevant if you are experiencing REM-related changes across your menstrual cycle. Progesterone naturally increases in the luteal phase and has mild sedative properties; adding lemborexant in the luteal phase may produce slightly amplified somnolence in some women, though this has not been studied in a controlled trial.

Phenotype 2: Women trying to conceive or currently pregnant

Dayvigo is not recommended during pregnancy. See the dedicated pregnancy and lactation section below for full detail. If you are actively trying to conceive, discuss timing and contraception planning with your clinician before starting lemborexant.

Phenotype 3: Perimenopausal women (typically 40-52)

Perimenopause is one of the highest-risk phenotypes for lemborexant side effects, for two reasons. First, erratic estrogen and progesterone fluctuations disrupt sleep architecture independently, meaning the insomnia being treated is already physiologically complex. Second, some women in this life stage are taking SSRIs, SNRIs, or other medications for mood or vasomotor symptoms, several of which interact with CYP3A4.

Lemborexant is metabolized primarily by CYP3A4. Moderate CYP3A4 inhibitors (fluconazole, fluvoxamine, erythromycin) can increase lemborexant plasma exposure substantially. The FDA label contraindicates use with strong CYP3A4 inhibitors and recommends a maximum dose of 5 mg with moderate inhibitors. Perimenopausal women recurrently treated for vulvovaginal candidiasis with fluconazole should be counseled on this interaction specifically.

Vasomotor symptoms (hot flashes and night sweats) also fragment sleep independently of orexin signaling, so lemborexant may provide incomplete relief at lower doses in this phenotype, prompting clinicians toward the 10 mg dose, which carries the higher somnolence and next-day impairment burden.

Phenotype 4: Postmenopausal women (over 52)

Age-related CYP3A4 activity declines modestly, meaning older postmenopausal women clear lemborexant more slowly than younger adults. Pharmacokinetic data from the FDA label show that AUC increases with age in adults over 65, and the label recommends caution in older adults, noting that the 10 mg dose carries a higher risk of falls and next-day impairment.

Falls are a critical concern. A FAERS disproportionality analysis published in 2023 identified falls and fractures as a significant post-market signal for dual orexin receptor antagonists including lemborexant, with older female patients over-represented among fall reports relative to their proportion of prescriptions. This finding is extrapolated from broader DORA-class data and is not lemborexant-specific in the published literature, but it aligns with the pharmacokinetic rationale.

Postmenopausal women already face elevated fracture risk from estrogen-deficient bone loss. A fall on lemborexant is therefore not merely a sedation inconvenience; it carries downstream skeletal risk. The American Geriatrics Society's Beers Criteria recommend that all orexin receptor antagonists be used with caution in older adults, citing fall and cognitive impairment risk.

Phenotype 5: Women with PCOS, obesity, or metabolic syndrome

Women with PCOS frequently experience sleep-disordered breathing including obstructive sleep apnea (OSA), driven partly by androgen excess and partly by central adiposity. The FDA label contraindicates lemborexant in patients with narcolepsy and recommends caution in those with compromised respiratory function including moderate-to-severe OSA.

If you have PCOS and undiagnosed or undertreated OSA, lemborexant may worsen nocturnal hypoxia by reducing arousals that are physiologically protective. Daytime somnolence severity may be substantially higher in this phenotype. A sleep study to rule out or characterize OSA before starting any sedating sleep aid is prudent clinical practice.

Obesity also affects lemborexant distribution. As a lipophilic compound, lemborexant distributes into adipose tissue, potentially extending its half-life in women with higher body fat percentage. The FDA label notes that body weight affects clearance but does not specify a dose adjustment. The practical implication is that somnolence may last longer into the next day in women with BMI >35.

Phenotype 6: Women with hepatic impairment

Lemborexant is contraindicated in severe hepatic impairment (Child-Pugh C). In moderate hepatic impairment (Child-Pugh B), the maximum recommended dose is 5 mg. Women with non-alcoholic fatty liver disease (NAFLD), which is increasingly prevalent in women with PCOS and metabolic syndrome, may have subclinical hepatic changes that affect drug metabolism even before reaching a formal Child-Pugh classification.

Rare but serious: what the FAERS data add

Post-market pharmacovigilance through the FDA Adverse Event Reporting System (FAERS) captures signals that clinical trials, with their controlled populations and limited duration, cannot always detect.

Complex sleep behaviors

The boxed warning in the lemborexant prescribing information states: "Complex sleep behaviors including sleepwalking, sleep driving, and engaging in other activities while not fully awake may occur. Some of these events may result in serious injuries or death." The FDA added this class-wide boxed warning to all sedative-hypnotics in 2019, but post-market case reports have confirmed its relevance to lemborexant specifically. FAERS reports include cases of sleep-eating and sleep-driving at both approved doses. Women who use lemborexant with alcohol, opioids, or other CNS depressants appear in case reports disproportionately, which reflects the pharmacodynamic interaction rather than a sex-specific signal per se.

Cataplexy-like events

In the SUNRISE trials, cataplexy-like episodes (sudden muscle weakness triggered by emotion) were reported in <1% of participants. Because orexin normally supports muscle tone during wakefulness, blocking it may rarely produce transient weakness. This is more theoretically concerning in women with pre-existing neuromuscular conditions or those taking muscle relaxants.

Sleep paralysis and hypnagogic hallucinations

These phenomena occur at the boundary of sleep and wakefulness and were reported in <2% of SUNRISE participants across doses. They are typically brief and non-dangerous but can be distressing. Women who already experience high anxiety or who have a trauma history may find these episodes particularly disturbing. Severity is classified as mild-to-moderate in most reports, but the psychological impact can exceed the physiological severity rating.

Pregnancy, lactation, and contraception

Dayvigo (lemborexant) should not be used during pregnancy. This is the clearest safety boundary for this drug in women's health.

Pregnancy data

Animal reproductive studies showed embryo-fetal toxicity at doses below the maximum recommended human dose. The FDA prescribing label states that there are no adequate and well-controlled studies in pregnant women. Lemborexant was not assigned a formal A/B/C/D/X letter category under the old FDA system (it was approved after the 2015 Pregnancy and Lactation Labeling Rule), but its risk summary is consistent with a profile that warrants avoidance.

Orexin signaling plays a role in fetal neurodevelopment and maternal physiological adaptation to pregnancy. Blocking OX1R and OX2R during critical developmental windows carries theoretical risk that has not been studied in humans.

Lactation

It is not known whether lemborexant or its active metabolites are present in human milk. Animal data show transfer into milk. Because of the potential for CNS effects in a nursing infant, the FDA label advises that the developmental and health benefits of breastfeeding be considered alongside the mother's clinical need for the drug and any potential adverse effects on the infant.

In practical terms: most clinicians managing insomnia in postpartum women will choose alternatives with a better-characterized lactation profile before considering lemborexant. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line approach endorsed by ACOG for insomnia in the perinatal period, precisely because pharmacologic options all carry some degree of uncertainty.

Contraception

Women of reproductive potential who need lemborexant should use reliable contraception. If pregnancy is suspected or confirmed, lemborexant should be discontinued immediately and obstetric care sought.

Drug interactions that amplify side-effect severity in women

Several drug interactions are disproportionately relevant to women because of conditions commonly managed in female patients.

CYP3A4 inhibitors raise lemborexant plasma concentrations. Fluconazole (frequently prescribed for vulvovaginal candidiasis) is a moderate-to-strong CYP3A4 inhibitor depending on dose and duration. Even a single-dose fluconazole 150 mg can transiently inhibit CYP3A4 and increase lemborexant exposure, potentially intensifying somnolence.

CNS depressants add pharmacodynamic burden. Women prescribed benzodiazepines for anxiety, or gabapentin for nerve pain or menopausal symptoms, face additive CNS depression. The severity of next-day impairment climbs with each added CNS-active agent.

Hormonal medications do not appear to interact with lemborexant metabolism through a direct pharmacokinetic pathway based on available data. However, the SUNRISE 2 trial data did not specifically report outcomes stratified by hormonal contraceptive or HRT use, so the interaction is not formally characterized.

Who is a good candidate and who should avoid Dayvigo

Women most likely to benefit with lower severity risk

Women who are a reasonable candidate for lemborexant at 5 mg with lower side-effect severity risk generally share these characteristics: age 18-55, no significant hepatic impairment, no concurrent strong CYP3A4 inhibitors, no untreated obstructive sleep apnea, and no current or planned pregnancy. Women who have not responded to CBT-I and who need a pharmacologic option with less tolerance risk than Z-drugs represent the core appropriate-use population.

Women who need extra caution or should avoid this drug

Women over 65 face heightened fall risk and should start at 5 mg with explicit counseling on morning hazards. Women with PCOS and unscreened OSA should have sleep-disordered breathing evaluated first. Women on moderate or strong CYP3A4 inhibitors should have their dose capped at 5 mg or the combination reconsidered. Women who are pregnant or breastfeeding should not use lemborexant and should discuss alternatives with their care team.

WomanRx editorial board member Maya Okafor, MD, notes: "The side-effect profile of lemborexant looks clean in a controlled trial population, but real-world women in perimenopause often arrive at the sleep clinic already on three or four medications. The interaction burden, not the drug in isolation, is where I see the most clinically significant adverse events."

Managing side effects if you are already taking Dayvigo

If you are currently taking Dayvigo and experiencing somnolence or next-day grogginess, a few adjustments are worth discussing with your clinician before stopping the medication.

Take it only when you have at least 7 hours available for sleep. The FDA label explicitly recommends this. Women who try to use it for a shorter sleep window predictably experience worse morning impairment.

If you are on 10 mg and tolerating it poorly, stepping down to 5 mg is supported by trial data showing meaningful efficacy at the lower dose with substantially lower somnolence rates. SUNRISE 1 showed statistically significant sleep onset latency improvement at both 5 mg and 10 mg versus placebo.

If you experience complex sleep behaviors (you wake up and find evidence of eating, moving around, or other activity you do not remember), stop lemborexant and contact your clinician the same day. This is not a "push through it" adverse event.

Evidence gaps specific to women

Women are historically under-represented in sleep disorder trials. A systematic review in Sleep Medicine Reviews documented that women represent, on average, 56% of insomnia trial participants but that sex-stratified adverse-event data are rarely reported as primary outcomes. The SUNRISE trials enrolled more women than men (roughly 60% female), which is better than many drug trials, but published adverse-event tables are not broken down by sex. This means every phenotype-specific statement in this article about women is either pharmacokinetically inferred or extrapolated from aggregate data.

The direct gaps that need filling: does CYP3A4 activity differ meaningfully by menstrual cycle phase in a way that affects lemborexant clearance? Do perimenopausal women discontinue lemborexant at higher rates than premenopausal women due to adverse events? Does lemborexant affect REM sleep differently in women who are post-menopause compared with those who are pre-menopause? None of these questions have been answered in published literature as of mid-2025.